{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T03:14:36Z","timestamp":1771298076939,"version":"3.50.1"},"reference-count":82,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.rdc.2018.06.010","type":"journal-article","created":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T04:56:52Z","timestamp":1536296212000},"page":"635-649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Thrombotic Microangiopathies with Rheumatologic Involvement"],"prefix":"10.1016","volume":"44","author":[{"given":"Faizan","family":"Babar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.rdc.2018.06.010_bib1","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.mayocp.2016.05.015","article-title":"Thrombotic microangiopathy care pathway: a consensus statement for the mayo clinic complement alternative pathway-thrombotic microangiopathy (CAP-TMA) disease-oriented group","volume":"91","author":"Go","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.rdc.2018.06.010_bib2","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic micro-angiopathy","volume":"371","author":"George","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.010_bib3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.imbio.2011.07.028","article-title":"Complement-mediated injury and protection of endothelium: lessons from atypical haemolytic uraemic syndrome","volume":"217","author":"Kerr","year":"2012","journal-title":"Immunobiology"},{"key":"10.1016\/j.rdc.2018.06.010_bib4","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1365-2141.2008.07074.x","article-title":"The VWF\/ADAMTS-13 axis antibodies and ADAMTS-13 dysfunction","volume":"141","author":"Austin","year":"2008","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.rdc.2018.06.010_bib5","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1053\/j.ajkd.2016.10.006","article-title":"AJKD atlas of renal pathology: thrombotic microangiopathy","volume":"68","author":"Lusco","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.rdc.2018.06.010_bib6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/01.ASN.0000108969.21691.5D","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"15","author":"Weening","year":"2004","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.rdc.2018.06.010_bib7","series-title":"Renal disease: classification and atlas of glomerular disease","author":"Churg","year":"1982"},{"key":"10.1016\/j.rdc.2018.06.010_bib8","series-title":"Renal disease: classification and atlas of glomerular diseases","author":"Churg","year":"1995"},{"issue":"15","key":"10.1016\/j.rdc.2018.06.010_bib9","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar4142","article-title":"The spectrum of renal thrombotic microangiopathy in lupus nephritis","volume":"1","author":"Song","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.010_bib10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1681\/ASN.V13142","article-title":"Antiphospholipid syndrome nephropathy in systemic lupus erythematosus","volume":"13","author":"Daugas","year":"2002","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.010_bib11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0049-0172(94)90072-8","article-title":"Thrombotic microangiograpthic hemolytic anemia in systemic lupus erythematosus. Review article","volume":"24","author":"Nesher","year":"1994","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.rdc.2018.06.010_bib12","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1002\/art.23662","article-title":"Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis","volume":"58","author":"Cohen","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.010_bib13","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/rheumatology\/keq311","article-title":"Thrombotic microangiopathy in systemic lupus erythematosus: a cohort study in North Taiwan","volume":"50","author":"Chen","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.rdc.2018.06.010_bib14","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1177\/0961203310368409","article-title":"Association between anti-\u03b22 glycoprotein antibodies and renal glomerular C4d deposition in lupus nephritis patients with glomerular microthrombosis: a prospective study of 155 cases","volume":"19","author":"Shen","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.rdc.2018.06.010_bib15","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1177\/0961203307083279","article-title":"Peritubular capillary C4d deposition in lupus nephritis different from antibody-mediated renal rejection","volume":"16","author":"Li","year":"2007","journal-title":"Lupus"},{"key":"10.1016\/j.rdc.2018.06.010_bib16","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1177\/0961203311415561","article-title":"Significance of glomerular activation of the alternative pathway and lectin pathway in lupus nephritis","volume":"20","author":"Sato","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.rdc.2018.06.010_bib17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0065-2776(08)04004-2","article-title":"The amplification loop of the contents complement pathways","volume":"104","author":"Lachmann","year":"2009","journal-title":"Adv Immunol"},{"key":"10.1016\/j.rdc.2018.06.010_bib18","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/eji.1830210337","article-title":"Human complement factor H: two factor H proteins are derived from alternatively spliced transcripts","volume":"21","author":"Estaller","year":"1991","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.rdc.2018.06.010_bib19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1681\/ASN.2010060647","article-title":"Complement factor H deficiency accelerates development of lupus nephritis","volume":"22","author":"Bao","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.rdc.2018.06.010_bib20","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1203\/PDR.0b013e3181b1bd4a","article-title":"Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1\/CFHR3 deficiency","volume":"66","author":"Lee","year":"2009","journal-title":"Pediatr Res"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.010_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0049-0172(98)80023-1","article-title":"Review of thrombotic thrombocytopenic purpura in the settings of systemic lupus erythematosus","volume":"28","author":"Musio","year":"1998","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.010_bib22","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3346\/jkms.1992.7.1.66","article-title":"Thrombotic thrombocytopenic purpura-like syndrome associated with systemic lupus erythematosus\u2013combined treatment with plasmapheresis and fresh frozen plasma infusion","volume":"7","author":"Lim","year":"1992","journal-title":"J\u00a0Korean Med Sci"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.010_bib23","first-page":"75","article-title":"Systemic lupus erythematosus and thrombotic thrombocytopenic purpura","volume":"102","author":"Roca-Tey","year":"1994","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.rdc.2018.06.010_bib24","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/rheumatology\/keq395","article-title":"Microangiopathic hemolytic anemia resembling thrombotic thrombocytopenia purpura, in systemic lupus erythematosus: the role of ADAMTS-13","volume":"50","author":"Lansigan","year":"2011","journal-title":"Rehumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.rdc.2018.06.010_bib25","first-page":"914","article-title":"Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis)","volume":"88","author":"Mannucci","year":"2003","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.010_bib26","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.freeradbiomed.2009.11.020","article-title":"Formation of methionine sulfoxide by peroxynitrite at position 1606 of vWF inhibits cleavage by ADAMTS-13. a new prothrombotic mechanism in a disease associated with oxidative stress","volume":"48","author":"Lancellotti","year":"2010","journal-title":"Free Radic Biol Med"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.010_bib27","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1182\/blood-2009-03-213967","article-title":"Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13","volume":"115","author":"Chen","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.010_bib28","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/rheumatology\/ken510","article-title":"A\u00a0comparison of thrombotic thrombocytopenia purpura in an inception cohort of patients with and without systemic lupus erythematosus","volume":"48","author":"Letchumanan","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2018.06.010_bib29","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10067-003-0742-1","article-title":"Systemic lupus erythematosus and thrombotic thrombocytopenia purpura: a case report and literature review","volume":"22","author":"Hamasaki","year":"2003","journal-title":"Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2018.06.010_bib30","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1007\/s10067-017-3823-2","article-title":"Use of eculizumab in a systemic lupus erythematosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review","volume":"36","author":"De Holanda","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.010_bib31","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/j.ajkd.2014.07.031","article-title":"Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab","volume":"65","author":"El-Husseini","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1016\/j.rdc.2018.06.010_bib32","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s10157-010-0300-5","article-title":"Rapidly progressive lupus nephritis and concomitant thrombotic microangiopathy","volume":"14","author":"Gharbi","year":"2010","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.010_bib33","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10067-017-3793-4","article-title":"TMA secondary to SLE: rituximab improves overall but not renal survival","volume":"37","author":"Sun","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.rdc.2018.06.010_bib34","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMra002974","article-title":"The antiphospholipid syndrome","volume":"346","author":"Levine","year":"2002","journal-title":"N\u00a0Engl Med"},{"key":"10.1016\/j.rdc.2018.06.010_bib35","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0272-6386(12)80543-9","article-title":"Renal thrombotic microangiopathy in patients with systemic lupus erythematosus and the antiphospholipid syndrome","volume":"20","author":"Hughson","year":"1992","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.rdc.2018.06.010_bib36","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.010_bib37","first-page":"1019","article-title":"The intrarenal vascular lesions associated with primary antiphospholipid syndrome","volume":"46","author":"Nochy","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.010_bib38","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients Euro-Phospholipid Project Group","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.010_bib39","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/08860229909066969","article-title":"Catastrophic antiphospholipid syndromes in systemic lupus erythematosus","volume":"21","author":"Stratta","year":"1999","journal-title":"Ren Fail"},{"key":"10.1016\/j.rdc.2018.06.010_bib40","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S0022-2143(98)90063-4","article-title":"Reactivity patterns of antiphospholipid antibodies and endothelial cells: effect of antiendothelial antibodies on cell migration","volume":"131","author":"Lanir","year":"1998","journal-title":"J\u00a0Lab Clin Med"},{"key":"10.1016\/j.rdc.2018.06.010_bib41","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood-2009-01-199117","article-title":"Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies","volume":"114","author":"Seshan","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.rdc.2018.06.010_bib42","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1111\/j.1600-6143.2011.03696.x","article-title":"Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation","volume":"11","author":"Hadaya","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.rdc.2018.06.010_bib43","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMoa1312890","article-title":"Inhibition of the mTORC pathway in the antiphospholipid syndrome","volume":"371","author":"Canaud","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.rdc.2018.06.010_bib44","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.reuma.2008.12.011","article-title":"Clinical significance of antiphospholipid syndrome nephropathy (APSN) in patients with systemic lupus erythematosus SLE","volume":"5","author":"Miranda","year":"2009","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.rdc.2018.06.010_bib45","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00005792-198103000-00001","article-title":"Glomerular thrombosis in systemic lupus erythematosus: prevalence and significance","volume":"60","author":"Kant","year":"1981","journal-title":"Medicine"},{"key":"10.1016\/j.rdc.2018.06.010_bib46","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/ki.1991.155","article-title":"Significance of anti-phospholipid antibodies in patients with lupus nephritis","volume":"39","author":"Frampton","year":"1991","journal-title":"Kidney Int"},{"key":"10.1016\/j.rdc.2018.06.010_bib47","first-page":"424","article-title":"Adaptive mechanism of counterbalancing enhanced thrombogenesis in antiphospholipid syndrome","volume":"71","author":"Musial","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rdc.2018.06.010_bib48","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1055\/s-0038-1642454","article-title":"Plasma levels of lipoprotein are elevated in patients with antiphospholipid antibody syndrome","volume":"71","author":"Yamazaki","year":"1994","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.010_bib49","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0272-6386(12)80885-7","article-title":"Renal vascular lesions as a marker of poor prognosis in patients with lupus nephritis Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL)","volume":"18","author":"Banfi","year":"1991","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1016\/j.rdc.2018.06.010_bib50","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2215\/CJN.00460110","article-title":"Renal involvement in primary antiphospholipid syndrome: retrospective analysis of 160 patients","volume":"5","author":"Sinico","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.010_bib51","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.kint.2016.06.026","article-title":"Antiphospholipid syndrome and kidney disease","volume":"91","author":"Bienaime","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.rdc.2018.06.010_bib52","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJMc0910965","article-title":"Eculizumab and renal transplantation in a patient with CAPS","volume":"362","author":"Lonze","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2018.06.010_bib53","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/art.34440","article-title":"A\u00a0brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab","volume":"64","author":"Shapira","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2018.06.010_bib54","doi-asserted-by":"crossref","first-page":"915309","DOI":"10.1155\/2013\/915309","article-title":"Catastrophic antiphospholipid syndrome with severe acute thrombotic microangiopathy and hemorrhagic complications","volume":"2013","author":"Vieregge","year":"2013","journal-title":"Case Rep Med"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.010_bib55","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ekir.2016.07.005","article-title":"Scleroderma renal crisis in a normotensive patient internal medicine\u2013nephrology, Christiana Care Health Services, Christiana Care Health System, Newark, Delaware, USA","volume":"1","author":"Asamoah-Odei","year":"2016","journal-title":"Kidney Int Rep"},{"issue":"9","key":"10.1016\/j.rdc.2018.06.010_bib56","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/anr.1780320911","article-title":"Renal failure in systemic sclerosis","volume":"32","author":"Helfrich","year":"1989","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2018.06.010_bib57","doi-asserted-by":"crossref","first-page":"543704","DOI":"10.1155\/2010\/543704","article-title":"Scleroderma renal crisis: a pathology perspective","volume":"2010","author":"Batal","year":"2010","journal-title":"Int J Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.010_bib58","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/16066350500095415","article-title":"New developments in the pathogenesis of systemic sclerosis","volume":"38","author":"Sakkas","year":"2005","journal-title":"Autoimmunity"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.010_bib59","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/07853890601098152","article-title":"Update on pathophysiology of scleroderma with special reference to immunoinflammatory events","volume":"39","author":"Chizzolini","year":"2007","journal-title":"Ann Med"},{"issue":"12","key":"10.1016\/j.rdc.2018.06.010_bib60","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.molimm.2004.06.025","article-title":"Altered B lymphocyte function ] induces systemic a to immunity in systemic sclerosis","volume":"41","author":"Sato","year":"2004","journal-title":"Mol Immunol"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.010_bib61","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1006\/clin.1998.4591","article-title":"Analysis of autoantibodies against RNA polymerases using immunoaffinity-purified RNA polymerase I, II, and III antigen in an enzyme-linked immunosorbent assay","volume":"89","author":"Chang","year":"1998","journal-title":"Clin Immunol Immunopathol"},{"issue":"7","key":"10.1016\/j.rdc.2018.06.010_bib62","first-page":"1528","article-title":"Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA","volume":"34","author":"Santiago","year":"2007","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2018.06.010_bib63","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s100670050132","article-title":"Immunohistological study of endothelin-1 and endothelin-A and B receptors in two patients with scleroderma renal crisis","volume":"18","author":"Kobayashi","year":"1999","journal-title":"Clin Rheumatol"},{"issue":"Suppl 3","key":"10.1016\/j.rdc.2018.06.010_bib64","first-page":"iii32","article-title":"UK Scleroderma Study Group (UKSSG) guidelines on the diagnosis and management of scleroderma renal crisis","volume":"48","author":"Denton","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.rdc.2018.06.010_bib65","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/qjmed\/hcm052","article-title":"Scleroderma renal crisis: patient characteristics and long-term outcomes","volume":"100","author":"Penn","year":"2007","journal-title":"QJM"},{"key":"10.1016\/j.rdc.2018.06.010_bib66","doi-asserted-by":"crossref","first-page":"600","DOI":"10.7326\/0003-4819-133-8-200010170-00010","article-title":"Long-term outcomes of scleroderma renal crisis","volume":"133","author":"Steen","year":"2000","journal-title":"Ann Intern Med"},{"issue":"Suppl 100(5)","key":"10.1016\/j.rdc.2018.06.010_bib67","first-page":"122","article-title":"N-terminal pro Brain Natriuretic Peptide as predictor of outcome in scleroderma renal crisis","volume":"34","author":"Chighizola","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rdc.2018.06.010_bib68","doi-asserted-by":"crossref","first-page":"369","DOI":"10.7326\/0003-4819-75-3-369","article-title":"Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients","volume":"75","author":"Medsger","year":"1971","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rdc.2018.06.010_bib69","doi-asserted-by":"crossref","first-page":"352","DOI":"10.7326\/0003-4819-113-5-352","article-title":"Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors","volume":"113","author":"Steen","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rdc.2018.06.010_bib70","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0889-857X(03)00016-4","article-title":"Scleroderma renal crisis","volume":"29","author":"Steen","year":"2003","journal-title":"Rheum Dis Clin North Am"},{"issue":"9052","key":"10.1016\/j.rdc.2018.06.010_bib71","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(05)61568-1","article-title":"Failure of losartan to control blood pressure in scleroderma renal crisis","volume":"349","author":"Caskey","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.rdc.2018.06.010_bib72","first-page":"397","article-title":"Complications in the use of angiotensin receptor blockers in the treatment of scleroderma renal crisis","volume":"44","author":"Steen","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.rdc.2018.06.010_bib73","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/qjmed\/hct111","article-title":"Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility","volume":"106","author":"Penn","year":"2013","journal-title":"QJM An Int J Med"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.010_bib74","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.ajkd.2009.02.015","article-title":"Endothelin receptor antagonism and renin inhibition as treatment options for scleroderma kidney","volume":"54","author":"Dhaun","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.rdc.2018.06.010_bib75","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"9638","key":"10.1016\/j.rdc.2018.06.010_bib76","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"ONTARGET investigators","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.rdc.2018.06.010_bib77","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O","article-title":"Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis","volume":"41","author":"Steen","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.010_bib78","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4103\/0971-4065.179207","article-title":"Thrombotic microangiopathy: an unusual cause of renal failure in rheumatoid arthritis","volume":"27","author":"Sakthirajan","year":"2017","journal-title":"Indian J Nephrol"},{"key":"10.1016\/j.rdc.2018.06.010_bib79","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1160\/TH08-12-0825","article-title":"Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases","volume":"102","author":"Matsuyama","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rdc.2018.06.010_bib80","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2169\/internalmedicine.33.484","article-title":"Renal thrombotic microangiopathy in a patient with rheumatoid arthritis and antiphospholipid syndrome: successful treatment with cyclophosphamide pulse therapy and anticoagulant","volume":"33","author":"Nomura","year":"1994","journal-title":"Intern Med"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.010_bib81","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1046\/j.1526-0968.1999.00166.x","article-title":"Thrombotic thrombocytopenic purpura in a patient with rheumatoid arthritis treated by plasmapheresis","volume":"3","author":"Kfoury Baz","year":"1999","journal-title":"Ther Apher"},{"key":"10.1016\/j.rdc.2018.06.010_bib82","unstructured":"Vanoni F, Jorgensen C, Parve P. A difficult case of juvenile dermatomyositis complicated by thrombotic microangiopathy and Purtscher-like retinopathy. From 18th Pediatric Rheumatology European Society (PReS) Congress Bruges, Belgium, 14\u20138 Sep. 2011. Abstract"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X18300632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X18300632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:18:07Z","timestamp":1760181487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X18300632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":82,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0889857X18300632"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2018.06.010","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombotic Microangiopathies with Rheumatologic Involvement","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2018.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}